Woman with Multiple sclerosis (MS) She says she stayed with weakening side effects after the NHS shifted to a cheaper medicine.
Julie Cawdrill is among the points of MS patients who say they have suffered regression in their condition after being transferred from the drug called Tysabri to one called Tyruko, from appeal to the damage of their health.
NHS England Hope Savings £ 1 Peace Over the next five years, crossing the biosimal drugs – medications shown that they cannot be clinically different from the original medicine, but are set far cheaper.
However, in the case of Miss Cowdrill, she left suffering from headaches and extreme fatigue and experienced the deterioration of mobility because she began taking the medicine in December 2024. years.
“I am and many others said he feels like we were regressed 10 or 15 years after all the work we did to improve. It’s as if the carpet was pulled out of you – it’s awful”, said Independent.
The regulatory agency for medicines and health care (MHRA) said that “aware” that some patients experienced side effects, but that the rigorous assessment “showed clinically meaningful differences” between drugs.
Mrs. Cowdrill first noticed that her body was behaving unusually in 2006. year when she was in the early twenties, after she left the nerve damage in her eye. Until 2009, at the age of 28, she began to notice “literally everything” went wrong with his health, and she was diagnosed with MS.
MS is a chronic autoimmune disease that affects the nervous system and violates communication between the brain and body. There is no medicine, but treatment and management of pain are available to help patients manage their condition.
Due to the rapid advancement of her illness, MS Cawdrill is set to Tysabri. Although he did not reverse the neurological damage, she could return her daily habits like shopping, driving his car and taking a daughter to school.
Last April, she was told that the drug can now be managed in injection, not intravenous infusion, and she agreed to transfer procedures.
However, the unwanted reaction associated with the way that is managed to the medicine means that until November could not walk and spend hours crying in the pain in A & E in the Queen Elizabeth hospital in Birmingham. Thus the doctors suggested the transition to Tyruko.
“The nurse told me that now I could take Tyruca and said it was exactly the same, and nothing would change every month. I didn’t get over every month. But my disability got worse.
“My life is falling apart, my walking is only awful, I fall every week. Every part of my body is worse than the switch.”
Despite the requirements for return to Tysabri, which took 13 years without issue, Ms. Cawdrill was informed that only Tyruko and injections were available from now, as part of the entire run.
Since it communicates with others online, she wrote a letter to NHS England, MS Trust and MS Society for supervision about drugs. The letter was signed by 103 colleagues of patients from 31 different hospitals.
She also launched a petition by asking for Tysabri access to return to those affected by switching. It attracted more than 37,000 signatures.
Attached to the Crusan Hospital, about 170 patients were transferred to Tysabri after suffering complications, including relapse their disease, from taking biosillas.
The spokesman of the pharmaceutical company Sandoz, who produces the drug, was approved by Tyruko (Natalizumab) in the UK with the Clinical Efficiency and Security. The Real Life Patients showed that the transfer from Tysabri in Tyro is well tolerated. “
The MS Trust spokesman said that they contacted patients who noticed “significant symptom changes” after transfer from Tysabri to Tyruko (both Natalizumab products).
“It is vital to fully understand the experiences of people with MS when transferring from a Natalizumab product to another. In order to ensure that these data is transparent with MS community and health teams responsible,” said spokesman.
Laura Thomas, Policy Head in MS society, said most people who changed treatment did it without any problems, but some reported problems.
“NHS England said that it should be possible for patients to experience harmful events or deterioration of TyRuka to return to Tysabri IV [the version that is delivered intravenously]. We ask them to make sure that happens in practice. ”
NHS England spokeswoman said that indicators have had medications that they do not have a clinically meaningful difference in their safety or efficiency, but to connect to MHR, manufacturers and patients follow concerns.
“Patient safety is our top priority,” MHRA said. “We are constantly monitoring the safety of the UK markets and we work on researching these problems using all available information, including yellow card reports and data from Tyruko marketing holder.”